Sham Mailankody, MBBS

About Dr. Mailankody

Dr. Mailankody is a medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in the treatment of multiple myeloma and related plasma cell disorders, including monoclonal gammopathy of undetermined significance and light chain amyloidosis. He serves as Clinical Director of the Cellular Therapy Service and Research Director of the Myeloma Service at Memorial Sloan Kettering Cancer Center.

Dr. Mailankody’s clinical and research work focuses on the development and advancement of novel immune and cellular therapies for plasma cell malignancies. His primary research interests include chimeric antigen receptor T-cell therapies and other immunotherapeutic approaches aimed at improving outcomes for patients with relapsed or refractory multiple myeloma. He leads and contributes to multiple clinical trials investigating first-in-human and early-phase cellular therapies.

Board certified in internal medicine and medical oncology, Dr. Mailankody completed his fellowship in medical oncology at the National Cancer Institute. He completed his residency in internal medicine at Georgetown University and Washington Hospital Center and earned his medical degree from K.S. Hegde Medical Academy.

In addition to his leadership roles, Dr Mailankody is actively involved in translational research and the design of innovative clinical trials intended to expand therapeutic options and define best practices in the evolving landscape of myeloma treatment.

He sees patients at the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center in New York, New York.